Cagrilintide Research Hub · Evidence Overview
Cagrilintide research evidence: amylin-receptor pharmacology and study limitations
A source-based review of receptor pharmacology, preclinical models, randomized clinical research, and the limits of what those studies establish.
Evidence at a glance
What is cagrilintide?
Cagrilintide is an engineered analogue of amylin, a pancreatic peptide hormone co-secreted with insulin. It was designed for prolonged exposure through lipidation and reversible binding to albumin. In the literature it is also described as AM833 and as a dual amylin and calcitonin receptor agonist.
That receptor profile matters. Amylin receptors are complexes built from the calcitonin receptor and receptor-activity-modifying proteins. Different receptor assemblies, tissues, experimental systems, and species can produce different responses. A finding in one assay or model cannot be treated as a universal claim about the compound.
Evidence map
| Research area | What was studied | Key limitation |
|---|---|---|
| Receptor pharmacology | Comparative assays measured activity across calcitonin-family receptors and multiple signaling endpoints. | In-vitro potency does not establish whole-organism or clinical outcomes. |
| Structural biology | Cryo-EM and functional assays examined binding to AMY1 and calcitonin receptors. | Receptor structures explain interactions, not clinical safety or effectiveness. |
| Animal neuroscience | Mouse studies examined receptor dependence, food intake, and activation of hindbrain pathways. | Species, diet, dose, route, and model constrain interpretation. |
| Monotherapy trial | A 26-week randomized phase 2 dose-finding study compared several cagrilintide groups with placebo and liraglutide. | A controlled trial product and protocol are not interchangeable with commercial research material. |
| Combination trials | Clinical studies evaluated cagrilintide administered with semaglutide. | Combination results cannot be attributed to cagrilintide alone. |
Amylin and calcitonin-family receptor signaling
A 2021 comparative pharmacology study described AM833 as a novel lipidated amylin analogue and tested it across 25 endpoints against selective and nonselective agonists. The authors reported a nonselective activity profile across amylin and calcitonin receptors. This kind of panel helps distinguish receptor pharmacology from assumptions based only on the parent hormone.
A 2025 mouse study used animals lacking RAMP1 and RAMP3 to examine whether AMY1 and AMY3 receptors contribute to cagrilintide-related changes in food intake and body weight. Loss of those receptor components reduced cagrilintide potency and altered neural activation patterns, supporting a role for specific amylin-receptor complexes in that model.
Structural work published online in 2025 reported cryo-electron microscopy structures of cagrilintide bound to AMY1 and calcitonin receptor complexes. The study described common binding features and Gs signaling at both receptors. Structural and cellular results clarify molecular interactions; they do not by themselves predict outcomes in an intact organism.
What the randomized studies reported
A multicenter phase 2 trial enrolled adults with overweight or obesity without diabetes and randomized participants to several once-weekly cagrilintide groups, liraglutide, or placebo. The 26-week study evaluated dose response, body-weight change, safety, and tolerability. It was designed around a defined investigational product, escalation schedule, eligibility criteria, and clinical supervision.
A separate 32-week randomized phase 2 trial in adults with type 2 diabetes compared co-administered cagrilintide and semaglutide with either component alone. Outcomes included glycated hemoglobin, body weight, fasting glucose, continuous-glucose-monitoring measures, and safety. Because the combination targets two different pathways, its findings should not be presented as evidence for cagrilintide alone.
Later phase 3 research has continued to study fixed-dose cagrilintide-semaglutide combinations in specific populations. Each protocol answers a defined question using controlled manufacturing, monitoring, inclusion criteria, and outcome definitions. Those studies do not authorize or validate use of JD BioWorks research material in people or animals.
Why study design matters
Evidence strength depends on the experimental question. Receptor assays can show binding and signaling. Animal models can test pathway dependence under controlled conditions. Randomized clinical trials can compare an investigational intervention within a specific protocol. None of those evidence types automatically answers questions outside its design.
Researchers should separate monotherapy data from combination data, mechanistic endpoints from clinical outcomes, and analytical verification of a vial from biological claims about a molecule. Results should also be read with attention to sponsor involvement, trial duration, attrition, adverse-event reporting, and whether analyses assume continued treatment or reflect actual adherence.
Analytical and documentation considerations
A literature summary cannot verify the identity of a physical sample. Laboratory procurement should connect the vial label and lot number to a lot-specific Certificate of Analysis and evaluate the methods used for identity, purity, and measured content.
- Match the compound name, labeled quantity, lot number, and report identifier.
- Review purity and identity as separate analytical questions.
- Compare the labeled quantity with measured net peptide content.
- Retain the original laboratory report and verification information with the research record.
For JD BioWorks lot 2026-003, the ILS Laboratories report identifies Cagrilintide, a labeled quantity of 5 mg, 99.14% peptide purity, 5.28 mg net peptide content, identity confirmed by HPLC retention-time matching, and fentanyl not detected. Those results describe the submitted sample only.
Major limitations in the evidence base
- Cell and animal findings do not establish human outcomes.
- Results from cagrilintide combined with semaglutide cannot be assigned to cagrilintide alone.
- Trial products and protocols are not interchangeable with commercial research samples.
- Short and medium-duration trials cannot answer every long-term safety question.
- Published research does not provide a basis for human or veterinary use of JD BioWorks materials.
Verified sources
- Hay DL, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021. PubMed PMID 33727283.
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021. PubMed PMID 34798060.
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023. PubMed PMID 37364590.
- Le Foll C, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025. PubMed PMID 40609154.
- Gu YM, et al. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacol Sin. 2026. PubMed PMID 40847076.
- ClinicalTrials.gov. Study NCT03856047: investigation of once-weekly cagrilintide in adults with overweight or obesity. ClinicalTrials.gov record.
Research record
- Compound
- Cagrilintide (AM833)
- Research class
- Lipidated amylin analogue; amylin and calcitonin-family receptor agonist
- Evidence reviewed
- Receptor assays, structural biology, animal neuroscience, and randomized clinical research
- Review date
- September 21, 2026
This article is an educational summary for qualified laboratory and analytical research. It is not medical advice and does not provide instructions for human or veterinary use. JD BioWorks materials are not for injection, ingestion, administration, application, or other use in humans or animals.